Difference between revisions of "GIHCG"
(Created page with "==Annotation== ===Name=== GIHCG ===Alias=== NA ===Disease=== Disease: hepatocellular cancer [http://www.ncbi.nlm.nih.gov/pubmed/27380494 (PMID:27380494)] Dysfunction type:...") |
Qianpeng Li (talk | contribs) |
||
| Line 1: | Line 1: | ||
| − | == | + | |
| + | ==Annotated Information== | ||
===Name=== | ===Name=== | ||
| − | GIHCG | + | Approved symbol: ''GIHCG'' |
| + | |||
| + | Approved name: GIHCG inhibitor of miR-200b/200a/429 expression | ||
| + | |||
| + | Alias symbols: lncRNA-GIHCG | ||
| − | + | HGNC ID: HGNC: 52649 | |
| − | |||
| − | + | RefSeq ID：NR_038269 | |
| − | |||
| − | + | Ensembl ID: ENSG00000257698 | |
| − | + | LncBook transcript ID: HSALNT0289851 | |
| + | ===Characteristics=== | ||
| + | - | ||
===Function=== | ===Function=== | ||
| − | + | [[File:GIHCG-exp1.png|right|thumb|400px|''GIHCG'' was highly expressed in TSCC samples.<ref name="ref2" />.]] | |
| + | [[File:GIHCG-exp2.png|right|thumb|400px|''GIHCG'' is upregulated in RCC tissues and indicates a poor prognosis.<ref name="ref3" />.]] | ||
| + | * ''GIHCG'' promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429<ref name="ref1" />. | ||
| + | |||
| + | * ''GIHCG'' increased tongue squamous cell carcinoma (TSCC) progression through negative modulation of miR‐429<ref name="ref2" />. | ||
| + | |||
| + | * The deletion of ''GIHCG'' significantly represses cell proliferation and migration of renal cell carcinoma (RCC) cells<ref name="ref3" /> | ||
| + | |||
| + | ===Regulation=== | ||
| + | - | ||
| + | |||
| + | ===Diseases=== | ||
| + | Hepatocellular cancer<ref name="ref1" /> | ||
| + | |||
| + | Tongue squamous cell carcinoma (TSCC)<ref name="ref2" /> | ||
| + | |||
| + | Renal cell carcinoma (RCC)<ref name="ref3" /> | ||
| + | ===Expression=== | ||
| + | The expression level of ''GIHCG'' was upregulated in TSCC tissues and cell lines<ref name="ref2" />. | ||
| + | |||
| + | The expression level of ''GIHCG'' in the serum of renal cell carcinoma (RCC) patients is significantly upregulated compared with that in healthy controls. GIHCG is markedly increased in RCC tissues with advanced TNM stages. Furthermore, ''GIHCG'' expression is also significantly increased in RCC tissues with Fuhrman III and IV grades compared with that in Fuhrman I and II grades<ref name="ref3" />. | ||
| + | |||
| + | {| class='wikitable' style="text-align:center" | ||
| + | |- | ||
| + | ! | Experiment | ||
| + | ! | Forward primer | ||
| + | ! | Reverse primer | ||
| + | |- | ||
| + | | rowspan="1"|Quantitative real-time PCR | ||
| + | | | 5'-CTTTCAAGAAGTTTGGCTGTC- 3' | ||
| + | | | 5'-GCTCATTCAACGGATAAGTC- 3'<ref name="ref1" /> | ||
| + | |} | ||
| − | + | ===Evolution=== | |
| + | - | ||
| − | + | ===Sequence=== | |
| + | >NR_038269.1 Homo sapiens GIHCG inhibitor of miR-200b/200a/429 expression (GIHCG), long non-coding RNA | ||
| + | <dnaseq>GGAGGAGTTACGCAGGCAGGGTTGTGGTTGCTGGCTGTTACCAGGACAACCGGAGGCGATTGACCGTTAT | ||
| + | CTGCGGTTTGGAGCCGTTAGCGGGAGAGGCAGAGATATTCAGAGGTCTTTTAGGATGCGCTAAAGGGTCG | ||
| + | TGAGGGCTCTCTTAAAATTTTCTTCACAAGCGGTTATCCAGTCGTGCCCCGCGGCCCTGCTGCTGGCCCC | ||
| + | GGGGATCTGAGTCGTACCCTCTTGTTTTTCTCTGAGTCAGTCTTAAGGTGAAATGAAGTGTGGCCCAGTG | ||
| + | GCTCCTCACTGTCGCTTCTCTAGTTTTCTGCCTCCTTTTAGAAAATTGAATTGAAAAGACAGGATGAAGT | ||
| + | GGACACAGCATGTGAAGACAATTCTTTCAAGAAGTTTGGCTGTCAAGGAAAACAGAGAATGTGCTAAAGA | ||
| + | ACATACAGACACAGAGCAGACAGGCCACCTTTGCAACCACATGGAGGTTTGTCTGATATTGAAGCTAAAG | ||
| + | AAGCTAAGCTGGAAGACAGAGAGACCAAGTCCTGATGACATTGTTTGAACCCAGAGATCCAGACATGCCT | ||
| + | GAAAACTAGTTTTACCACTGGACTTATCCGTTGAATGAGCCAATAAACTCTCTTTTATACTTAACCTTGG | ||
| + | GTTTTACCTGGATTTTTGTCATTGACAGCTCAAAATATTCTAATATAGAAGTATACATCATTAAATCAAA | ||
| + | AAAAAAAAAAA</dnaseq> | ||
| + | ==Labs working on this lncRNA== | ||
| + | *Department of Periodontology, Jinan Stomatological Hospital, Jinan, Shandong,China. | ||
| + | *Department of Nephrology, The People's Hospital of Yichun City, Yichun, Jiangxi, China. | ||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> | ||
| + | Sui C, Zhou Y, Shen W, et al. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429[J]. Journal of molecular medicine, 2016, 94(11): 1281-1296. | ||
| + | </ref> | ||
| + | <ref name="ref2"> | ||
| + | Ma L, Wang Q, Gong Z, et al. Long noncoding RNA GIHCG enhanced tongue squamous cell carcinoma progression through regulating miR‐429[J]. Journal of cellular biochemistry, 2018, 119(11): 9064-9071. | ||
| + | </ref> | ||
| + | <ref name="ref3"> | ||
| + | He Z H, Qin X H, Zhang X L, et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1): 46-54. | ||
| + | </ref> | ||
| + | </references> | ||
Latest revision as of 02:15, 15 August 2019
Contents
Annotated Information
Name
Approved symbol: GIHCG
Approved name: GIHCG inhibitor of miR-200b/200a/429 expression
Alias symbols: lncRNA-GIHCG
HGNC ID: HGNC: 52649
RefSeq ID：NR_038269
Ensembl ID: ENSG00000257698
LncBook transcript ID: HSALNT0289851
Characteristics
-
Function
GIHCG was highly expressed in TSCC samples.[1].
GIHCG is upregulated in RCC tissues and indicates a poor prognosis.[2].
- GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429[3].
- GIHCG increased tongue squamous cell carcinoma (TSCC) progression through negative modulation of miR‐429[1].
- The deletion of GIHCG significantly represses cell proliferation and migration of renal cell carcinoma (RCC) cells[2]
Regulation
-
Diseases
Hepatocellular cancer[3]
Tongue squamous cell carcinoma (TSCC)[1]
Renal cell carcinoma (RCC)[2]
Expression
The expression level of GIHCG was upregulated in TSCC tissues and cell lines[1].
The expression level of GIHCG in the serum of renal cell carcinoma (RCC) patients is significantly upregulated compared with that in healthy controls. GIHCG is markedly increased in RCC tissues with advanced TNM stages. Furthermore, GIHCG expression is also significantly increased in RCC tissues with Fuhrman III and IV grades compared with that in Fuhrman I and II grades[2].
| Experiment | Forward primer | Reverse primer |
|---|---|---|
| Quantitative real-time PCR | 5'-CTTTCAAGAAGTTTGGCTGTC- 3' | 5'-GCTCATTCAACGGATAAGTC- 3'[3] |
Evolution
-
Sequence
>NR_038269.1 Homo sapiens GIHCG inhibitor of miR-200b/200a/429 expression (GIHCG), long non-coding RNA
000001 GGAGGAGTTA CGCAGGCAGG GTTGTGGTTG CTGGCTGTTA CCAGGACAAC CGGAGGCGAT TGACCGTTAT CTGCGGTTTG 000080
000081 GAGCCGTTAG CGGGAGAGGC AGAGATATTC AGAGGTCTTT TAGGATGCGC TAAAGGGTCG TGAGGGCTCT CTTAAAATTT 000160
000161 TCTTCACAAG CGGTTATCCA GTCGTGCCCC GCGGCCCTGC TGCTGGCCCC GGGGATCTGA GTCGTACCCT CTTGTTTTTC 000240
000241 TCTGAGTCAG TCTTAAGGTG AAATGAAGTG TGGCCCAGTG GCTCCTCACT GTCGCTTCTC TAGTTTTCTG CCTCCTTTTA 000320
000321 GAAAATTGAA TTGAAAAGAC AGGATGAAGT GGACACAGCA TGTGAAGACA ATTCTTTCAA GAAGTTTGGC TGTCAAGGAA 000400
000401 AACAGAGAAT GTGCTAAAGA ACATACAGAC ACAGAGCAGA CAGGCCACCT TTGCAACCAC ATGGAGGTTT GTCTGATATT 000480
000481 GAAGCTAAAG AAGCTAAGCT GGAAGACAGA GAGACCAAGT CCTGATGACA TTGTTTGAAC CCAGAGATCC AGACATGCCT 000560
000561 GAAAACTAGT TTTACCACTG GACTTATCCG TTGAATGAGC CAATAAACTC TCTTTTATAC TTAACCTTGG GTTTTACCTG 000640
000641 GATTTTTGTC ATTGACAGCT CAAAATATTC TAATATAGAA GTATACATCA TTAAATCAAA AAAAAAAAAA A
000081 GAGCCGTTAG CGGGAGAGGC AGAGATATTC AGAGGTCTTT TAGGATGCGC TAAAGGGTCG TGAGGGCTCT CTTAAAATTT 000160
000161 TCTTCACAAG CGGTTATCCA GTCGTGCCCC GCGGCCCTGC TGCTGGCCCC GGGGATCTGA GTCGTACCCT CTTGTTTTTC 000240
000241 TCTGAGTCAG TCTTAAGGTG AAATGAAGTG TGGCCCAGTG GCTCCTCACT GTCGCTTCTC TAGTTTTCTG CCTCCTTTTA 000320
000321 GAAAATTGAA TTGAAAAGAC AGGATGAAGT GGACACAGCA TGTGAAGACA ATTCTTTCAA GAAGTTTGGC TGTCAAGGAA 000400
000401 AACAGAGAAT GTGCTAAAGA ACATACAGAC ACAGAGCAGA CAGGCCACCT TTGCAACCAC ATGGAGGTTT GTCTGATATT 000480
000481 GAAGCTAAAG AAGCTAAGCT GGAAGACAGA GAGACCAAGT CCTGATGACA TTGTTTGAAC CCAGAGATCC AGACATGCCT 000560
000561 GAAAACTAGT TTTACCACTG GACTTATCCG TTGAATGAGC CAATAAACTC TCTTTTATAC TTAACCTTGG GTTTTACCTG 000640
000641 GATTTTTGTC ATTGACAGCT CAAAATATTC TAATATAGAA GTATACATCA TTAAATCAAA AAAAAAAAAA A
Labs working on this lncRNA
- Department of Periodontology, Jinan Stomatological Hospital, Jinan, Shandong,China.
- Department of Nephrology, The People's Hospital of Yichun City, Yichun, Jiangxi, China.
References
- ↑ 1.0 1.1 1.2 1.3 Ma L, Wang Q, Gong Z, et al. Long noncoding RNA GIHCG enhanced tongue squamous cell carcinoma progression through regulating miR‐429[J]. Journal of cellular biochemistry, 2018, 119(11): 9064-9071.
- ↑ 2.0 2.1 2.2 2.3 He Z H, Qin X H, Zhang X L, et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1): 46-54.
- ↑ 3.0 3.1 3.2 Sui C, Zhou Y, Shen W, et al. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429[J]. Journal of molecular medicine, 2016, 94(11): 1281-1296.
